Complement Activation Markers in 128 Patients with Post-Acute COVID-19 Sequelae

38 patients with PASC after mild COVID-19, 10 after severe COVID-19, and 80 recovered controls were analyzed for complement activation markers C3bc, C3bBbP, and TCC up to 33 months post-infection. The dataset, authored by Madlene Holmqvist and shared under CC-BY-4.0, presents results from a study investigating dysregulation of the complement system as a potential mechanism for PASC. No significant differences in complement activation markers were found between PASC patients and controls.

Use Cases

• Compare complement activation marker levels between PASC patients and recovered controls based on the cohort composition described.
• Investigate the relationship between initial COVID-19 severity and subsequent complement system activity based on the patient stratification mentioned.
• Analyze longitudinal trends in immune dysregulation up to 33 months post-infection based on the study timeframe.
• Validate or refute the hypothesis of complement system involvement in PASC pathophysiology based on the measured biomarkers.

Strengths

• Includes a control group of 80 subjects who recovered completely from COVID-19 for comparison.
• Measures three specific complement activation markers (C3bc, C3bBbP, TCC) as described in the methods.
• Follows patients for an extended period, up to 33 months after initial infection.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (19.7 KB), indicating limited scope and sample size.

Provenance

Source

figshare

Collection Method

Analysis of complement activation markers in a defined patient cohort.

Time Range

Up to 33 months after initial SARS-CoV-2 infection.

Freshness

Last updated 2026-05-13 05:57:45; freshness should be verified.